High Sensitivity and NPV for BinaxNOW Rapid Antigen Test in Children at a Mass Testing Site during Prevalent Delta Variant Period

Author:

Sun Kristie J.1ORCID,Vaeth Mary Jane E.2,Robinson Matthew3ORCID,Elhabashy Maryam4,Gupta Ishaan3,Purekal Sophia2,Hammershaimb E. Adrianne5,Peralta Ria26,Mitchell Asia2,Foyez Maisha2,Johnson J. Kristie7,Ficke James R.8,Manabe Yukari C.3,Campbell James D.5,Callahan Charles W.7,Locke Charles F.3,Kantsiper Melinda9,Siddiqui Zishan K.3ORCID,Fink Jeffrey,Mitchtalik Henry,Eid Shaker M.,Wagner Lee Ann,Phillips Mark,

Affiliation:

1. Case Western Reserve University School of Medicine, Cleveland, Ohio, USA

2. Baltimore Convention Center Field Hospital, Baltimore, Maryland, USA

3. Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

4. University of Maryland Baltimore County, Baltimore, Maryland, USA

5. Center for Vaccine Development and Global Health, Department of Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland, USA

6. Nova Southeastern University College of Osteopathic Medicine, Fort Lauderdale, Florida, USA

7. Department of Pathology, University of Maryland School of Medicine, Baltimore, Maryland, USA

8. Department of Orthopedic Surgery, The Johns Hopkins University, Baltimore, Maryland, USA

9. Division of Hospital Medicine, The Johns Hopkins Bayview Medical Center, Baltimore, Maryland, USA

Abstract

The BinaxNOW rapid antigen COVID-19 test had a sensitivity of nearly 92% in both symptomatic and asymptomatic children when performed at a high-throughput setting during the more transmissible delta variant dominant period. The test may play an invaluable role in asymptomatic screening and keeping children safe in school.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Cell Biology,Microbiology (medical),Genetics,General Immunology and Microbiology,Ecology,Physiology

Reference27 articles.

1. Kates J Tolbert J Rouw A. 2021. An update on vaccine roll-out for 5–11 year-olds in the U.S. Kaiser Family Foundation San Francisco CA. https://www.kff.org/coronavirus-covid-19/issue-brief/an-update-on-vaccine-roll-out-for-5-11-year-olds-in-the-u-s/. Accessed 22 December 2021.

2. American Academy of Pediatrics. 2021. Children and COVID-19 vaccination trends. http://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/children-and-covid-19-vaccination-trends/. Accessed 22 December 2021.

3. New COVID-19 Cases and Hospitalizations Among Adults, by Vaccination Status — New York, May 3–July 25, 2021

4. Li Ka Shing Faculty of Medicine. 2021. HKUMed finds Omicron SARS-CoV-2 can infect faster and better than Delta in human bronchus but with less severe infection in lung. The University of Hong Kong Hong Kong China. https://www.med.hku.hk/en/news/press/20211215-omicron-sars-cov-2-infection. Accessed 22 December 2021.

5. Dorn E Hancock B Sarakatsannis J Viruleg E. 2021. COVID-19 and education: the lingering effects of unfinished learning. McKinsey & Company Atlanta GA. https://www.mckinsey.com/industries/education/our-insights/covid-19-and-education-the-lingering-effects-of-unfinished-learning

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3